MICC:EURONEXT AMSTERDAMMagnum Ice Cream Co. N.V. Analysis
Data as of 2026-03-14 - not real-time
$15.50
Latest Price
7/10Risk
Risk Level: Medium
Executive Summary
The stock is trading below its short‑, medium‑ and long‑term moving averages, with a mid‑forties RSI and a bearish MACD histogram, indicating limited near‑term upside. Volume is on a downtrend and 30‑day volatility is elevated, while the beta is slightly above market, suggesting higher price swings. Valuation metrics such as the price‑to‑earnings ratio sit in the high‑twenties and price‑to‑book is markedly elevated, pointing to an overvalued stance relative to fundamentals, especially given a substantial debt load that dwarfs cash reserves. However, forward earnings estimates compress the PE to a more attractive level, and recent material developments – a new non‑executive director, inclusion in the AEX index, and the post‑spin‑off rally – provide a growth narrative that could support a medium‑term rebound.
Overall, the defensive consumer sector offers stability, but the combination of high leverage, lofty valuation multiples, and pronounced volatility tempers enthusiasm. Investors should weigh the short‑term technical weakness against the longer‑term upside potential tied to earnings improvements and index exposure.
Overall, the defensive consumer sector offers stability, but the combination of high leverage, lofty valuation multiples, and pronounced volatility tempers enthusiasm. Investors should weigh the short‑term technical weakness against the longer‑term upside potential tied to earnings improvements and index exposure.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- Price below key moving averages and bearish MACD
- Decreasing volume and high short‑term volatility
- Overvalued multiples relative to current earnings
Medium Term
1–3 yearsPositive
Model confidence: 7/10
Key Factors
- Forward earnings compression reducing the PE
- Inclusion in the AEX index enhancing visibility
- Post‑spin‑off momentum and new board appointment
Long Term
> 3 yearsNeutral
Model confidence: 5/10
Key Factors
- Strong brand in a defensive consumer segment
- High debt burden limiting financial flexibility
- Potential for margin improvement if leverage is reduced
Key Metrics & Analysis
Financial Health
Revenue Growth-4.10%
Profit Margin3.70%
P/E Ratio28.2
ROE17.88%
ROA5.58%
Debt/Equity539.65
P/B Ratio13.1
Op. Cash Flow$483.0M
Free Cash Flow$204.0M
Technical Analysis
TrendNeutral
RSI44.1
Support$14.89
Resistance$17.01
MA 20$15.78
MA 50$16.49
MA 200$16.29
MACDBearish
VolumeDecreasing
Fear & Greed Index72.88
Valuation
Target Price$18.33
Upside/Downside18.28%
GradeOvervalued
TypeGrowth
Risk Assessment
Beta1.09
Volatility69.51%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskMedium
Similar Tickers
2050
Caixabank Destino 2050 Estándar FI
STOCK1999
Man Wah Holdings Limited
STOCK002236
Zhejiang Dahua Technology Co., Ltd.
STOCK001965
China Merchants Expressway Network & Technology Holdings Co.,Ltd.
STOCK600012
Anhui Expressway Company Limited Class A
STOCK956
China Suntien Green Energy Corporation Limited Class H
STOCKThis analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.